bioihbjkbjnl/mcl2 huggingface dataset:
Turkish Version of the Movement Imagery Questionnaire-3
Condition: Image, Body
Study type: Observational

Summary: 
      Motor imagery is the mental representation of movement without any body movement. According
      to recent studies motor imagery contains three strategies to mentally simulate the movements:
      internal visual, external visual and kinesthetic imagery. Motor imagery is associated with
      cortical reorganization and functional improvements and it does not only related with motor
      performance, it also influces cognitions. Movement Imagery Questionnaire-3 (MIQ-3) is the
      recent, modified version of the Movement Imagery Questionnaire-Revised, Second Edition and
      measures imagery ability in terms of ease of imagery.

      The aim of this study is to translate MIQ-3 into Turkish and evaluate its test-retest
      reliability for Turkish-speaking population.
    


Intervention name(s): Determining Imaginary levels
Intervention type(s): Behavioral
Intervention description(s): Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
Observational model: Other
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Healthy volunteers
      
Keywords: imaginary; Turkish version; motor imagery; reliability
Ischemic Conditioning as an Intervention to Improve Motor Function in Chronic Stroke
Condition: Stroke
MeSH terms: Stroke
Study type: Interventional

Summary: 
      The investigators will test whether an intervention called ischemic conditioning can improve
      paretic leg motor function in chronic stroke subjects.
    

Detailed description: 
      This study will study ischemic conditioning (IC) as an intervention to improve motor function
      post-stroke. IC is a well studied, well tolerated intervention which has been shown to
      improve regional blood flow, motor neuron excitability and muscle function in multiple
      patient groups and in young, healthy subjects. Because IC targets three physiological systems
      which are all affected by stroke, the investigators hypothesize that repeated bouts of IC
      will result in improved motor function of the paretic leg.
    

Intervention name(s): Ischemic Conditioning; Sham
Intervention type(s): Other; Other
Intervention description(s): Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.; Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Single Dose Bronchodilatory Study in Asthma
Condition: Asthma
MeSH terms: Asthma
Study type: Interventional
Phase: Phase 4

Summary: 
      Study to evaluate the bronchodilator effects of Zyflo CR in patients with chronic stable
      asthma.
    


Intervention name(s): Zileuton extended release
Intervention type(s): Drug
Intervention MeSH terms: Zileuton
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
MeSH terms: Multiple Myeloma; Neoplasms, Plasma Cell
Study type: Interventional
Phase: Phase 2

Summary: 
      Subjects up to the age of 65 years with newly diagnosed multiple myeloma requiring treatment
      are eligible. Minimal pretreatment (2 cycles of chemotherapy; local irradiation; surgery) is
      permitted. After enrollment, patients are to receive four cycles of RAD induction treatment:
      a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone. If at least a
      minimal response is achieved to RAD, they will undergo chemomobilization (cyclophosphamide,
      etoposide) of peripheral blood stem cells and one uniform cycle of high-dose melphalan
      chemotherapy followed by a first stem cell transplant. If any of the high-risk features (such
      as elevated beta 2-microglobulin, adverse cytogenetic factors, elevated LDH, Ig A isotype)
      were present at diagnosis, patients will be allocated to a consolidative allogeneic
      transplant following dose-reduced conditioning. If no appropriate donor is available, the
      patient does not consent or lacks of high-risk features a second autograft following
      high-dose melphalan will be delivered. All patients will proceed to lenalidomide maintenance
      (one year) following hematopoietic reconstitution.
    


Intervention name(s): allogeneic stem cell transplant versus second autologous transplantation; RAD
Intervention type(s): Procedure; Drug
Intervention description(s): Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²; After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Allogeneic stem cell transplantation; Lenalidomide; IMiD
Dexamethasone Compared With Dexmedetomidine as an Adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block
Condition: Brachial Plexus Block
Study type: Interventional
Phase: Phase 3

Summary: 
      The investigators want to compare the effectiveness of dexamethasone and dexmedetomidine as
      an adjuvant to 0.5% ropivacaine for supraclavicular brachial plexus block on the onset of
      block and duration of analgesia, so that the investigators can choose the better adjuvant for
      the investigators routine practice of regional anesthesia.
    

Detailed description: 
      Ropivacaine is a newer local anesthetic which is structurally related to bupivacaine, but has
      fewer side effects. It is more cardio stable than bupivacaine, but the onset of action is
      delayed and the duration of action is shorter than bupivacaine making its use during regional
      anesthesia less preferable to many anesthesiologists. Steroids like dexamethasone, or alpha-2
      agonists like dexmedetomidine are being studied as adjuvants to ropivacaine for brachial
      plexus block to improve its anesthetic properties and have shown favorable outcome in terms
      of shortening the onset of block and prolonging the duration of action. But no study has been
      done to compare their effects. So in this study the investigators want to compare the
      effectiveness of dexamethasone and dexmedetomidine as an adjuvant to 0.5% ropivacaine for
      supraclavicular brachial plexus block on the onset of block and duration of analgesia, so
      that the investigators can choose the better adjuvant for the investigators routine practice
      of regional anesthesia.
    

Intervention name(s): Ropivacaine and Normal saline; Ropivacaine and Dexamethasone; Ropivacaine and Dexmedetomidine
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline; Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone; Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
Intervention MeSH terms: Dexamethasone; Dexmedetomidine; Ropivacaine
Allocation: Randomized
Intervention model: Factorial Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Supportive Care
Keywords: Brachial plexus block; Ropivacaine; Dexmedetomidine; Dexamethasone; Adjuvants, anesthesia
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
Condition: Prevention of Herpes Zoster (HZ)
MeSH terms: Herpes Zoster
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a Phase 1, first in human (FIH), randomised, active-controlled, double-blind study
      designed to assess the safety and tolerability and explore preliminary efficacy of the EG-HZ
      vaccine. Oversight will be provided by a Safety Review Committee (SRC).
    

Detailed description: 
      Subjects will undergo a Screening period beginning up to 28 days prior to randomisation, the
      first of two vaccinations administered 2 months apart, pre- and post-dose assessment,
      follow-up visits, and an end of study (EOS) or early termination (ET) visit (as applicable).

      Subjects will be randomised prior to vaccination on Day 1, to one (1) of five (5) treatment
      groups.
    

Intervention name(s): Treatment 1 (EG-HZ-001); Treatment 2 (EG-HZ-002); Treatment 3 (EG-HZ-003); Treatment 4 (EG-HZ-004); Treatment 5
Intervention type(s): Drug; Drug; Drug; Drug; Drug
Intervention description(s): Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
Route of Administration: IM injection; Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
Route of Administration: IM injection; Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
Route of Administration: IM injection; Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
Route of Administration: IM injection; Shingrix
Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.
Route of Administration: IM injection
Other intervention name(s): EG-HZ; EG-HZ; EG-HZ; EG-HZ; Comparator
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
Condition: Healthy Volunteers
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to determine the effect of repeated doses of cefiderocol on the
      PK of midazolam.
    


Intervention name(s): Midazolam; Cefiderocol
Intervention type(s): Drug; Drug
Intervention description(s): Syrup for oral administration; Liquid for intravenous infusion
Intervention MeSH terms: Midazolam
Intervention model: Sequential Assignment
Masking: None (Open Label)
Primary purpose: Treatment
The Cholesterol-lowering Efficacy of Probiotic Lactobacillus Plantarum in Hypercholesterolaemic Adults
Condition: Healthy
Study type: Interventional

Summary: 
      Coronary heart disease (CHD) is one of the major causes of death and disability in
      industrialised countries. Results from several epidemiological and clinical studies indicate
      a positive correlation between elevated total serum cholesterol levels, mainly reflecting the
      LDL-cholesterol fraction, and risk of CHD. It is thought that a reduction in total plasma
      cholesterol levels in populations suffering from primary hypercholesterolemia (elevated
      cholesterol) can lower the incidence of coronary thrombosis. Currently, therefore there is
      extensive interest in the management of serum cholesterol and other blood lipids. Diet is
      viewed as a major influencing factor that can reduce levels. This is largely driven by the
      expense of drug therapy, the large numbers of individuals affected and unwanted side effects
      of such treatments. Dietary strategies for prevention of CHD implicate adherence to a
      low-fat/low-saturated fat diet. Although such diets may present an effective approach, they
      are difficult to maintain on a long-term basis and efficacy diminishes over time. As such,
      new approaches towards identification of other dietary means of reducing blood cholesterol
      levels have been evaluated. These include, among others, the use of probiotics. Probiotics
      are 'live microbial feed supplements that offer a benefit to health'. They are marketed as
      health or functional foods whereby they are ingested for their purported positive advantages
      in the digestive tract and/or systemic areas like the liver, vagina or bloodstream. The main
      goal of the study was to test whether probiotics can directly degrade cholesterol as well as
      produce metabolites that interfere with its synthesis in the liver. The effect may also be
      partially ascribed to an enzymatic deconjugation of bile acids.
    

Detailed description: 
      The aim of this human volunteer study was to establish tolerance, and the extent of the
      cholesterol lowering potential of Lactobacillus plantarum ECGC 13110402 in 49, healthy,
      normal to mildly hypercholesterolaemic adults (30-65 years old).
    

Intervention name(s): Lactobacillus plantarum ECGC 13110402; Maltodextrin
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): Lactobacillus plantarum ECGC 13110402
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Single-centre, prospective, randomised, placebo-controlled, parallel-group design to determine the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a drug interaction study evaluating the pharmacokinetic profiles of amoxicillin
      administered alone & in combination with MMX Mesalazine/mesalamine.
    


Intervention name(s): Amoxicillin + MMX placebo; Amoxicillin + MMX mesalazine/mesalamine
Intervention type(s): Drug; Drug
Intervention description(s): MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.; MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
Other intervention name(s): Lialda®
Intervention MeSH terms: Amoxicillin; Mesalamine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Robotic-assisted Therapy With Bilateral Practice Improves Task and Motor Performance of the Upper Extremity for Chronic Stroke Patients
Condition: Stroke Rehabilitation
MeSH terms: Stroke
Study type: Interventional

Summary: 
      Task-specific repetitive training, an usual care in occupational therapy practice, and
      robotic-aided rehabilitation with bilateral practice to improve limb's movement control has
      been popularised; however the difference in treatment effects between this two therapeutic
      strategies has been rarely described. The aim of the study was to compare the efficacy of
      robotic-assisted therapy with bilateral practice (RTBP) and usual care on task and motor
      performance for chronic stroke patients.
    


Intervention name(s): Robotic-assisted Therapy with Bilateral Practice; Unilateral Task-specific Training; Sensorimotor Stimulation Program
Intervention type(s): Other; Other; Other
Intervention description(s): 40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.; 40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.; 10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Stroke; Robotic-Assisted Therapy; Bilateral Practice; Task-specific Training; Rehabilitation
Correlation Between Body Weight and Foot Progression Angle in Adolescents
Condition: Obesity, Adolescent; Adolescent Development
MeSH terms: Pediatric Obesity; Body Weight
Study type: Observational [Patient Registry]

Summary: 
      Obesity is associated with functional decline , altered spatiotemporal gait parameters (e.g.
      lower gait speed, shorter strides, and increased step width), and a significantly higher
      metabolic cost of walking compared to people with normal body weight. Obesity also negatively
      affects balance control.This study will investigate foot progression angle in adolescents
      related to their weight and category classification based on the CDC (Centers for Disease
      Control and Prevention) growth charts.
    


Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        Two hundred healthy non-athletic children from both sexes will participate in this study.
Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer
Condition: Breast Cancer
MeSH terms: Breast Neoplasms
Study type: Interventional

Summary: 
      The trial population of this study is composed of women aged more than 18, who have developed
      a newly node-negative (or pN1mi), Estrogen Receptor (ER)-positive, Her2-negative invasive
      breast cancer with uncertainty on the indication of adjuvant chemotherapy using standard
      assessments.

      Obtaining material for test is at no risk as done from the surgery material. Tumor molecular
      EndoPredict (EP)clin analysis will allow to obtain information on the expression of 8 breast
      cancer related genes and will provide important prognosis indications. Clinical validation
      studies have demonstrated that molecular assays are useful for stratifying patients into risk
      categories and helpful in making clinical treatment decisions in ER+/node-negative breast
      cancer patients.
    


Intervention name(s): EPClin genomic test
Intervention type(s): Other
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Other
Keywords: Genomic test; Chemotherapy decision
Study of BHV-3241 in Participants With Multiple System Atrophy
Condition: Multiple System Atrophy
MeSH terms: Multiple System Atrophy; Shy-Drager Syndrome; Atrophy
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus
      placebo in participants with Multiple System Atrophy
    


Intervention name(s): Verdiperstat; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): 300mg 2 oral tablets, twice daily; Matching placebo
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Multiple System Atrophy (MSA)
Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to evaluate the safety and tolerability of repeated doses of a
      new investigational drug (ACU-4429) in healthy human subjects.
    


Intervention name(s): ACU-4429; matching placebo tablet
Intervention type(s): Drug; Drug
Intervention description(s): administered orally once a day for 14 days; administered orally once a day for 14 days
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Sun Protection Factor Assay
Condition: Sunscreening Agent
Study type: Interventional

Summary: 
      To evaluate the Sun Protection Factor efficacy on human skin.
    


Intervention name(s): Coppertone (BAY987517)
Intervention type(s): Drug
Intervention description(s): Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-74_R84-086)
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Study on the Safety of Abatacept in Relapsing Polychondritis
Condition: Relapsing Polychondritis
MeSH terms: Polychondritis, Relapsing
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to test the safety of the study drug abatacept and see what
      effects (good and bad) it has in patients with relapsing polychondritis.
    

Detailed description: 
      After a screening period of up to 4 weeks, patients who fulfill all inclusion and exclusion
      criteria will receive open-label subcutaneous abatacept consisting of 125 mg weekly,
      beginning 1 week thru Week 24.

      Throughout the study, blood will be collected for clinical laboratory safety,
      pharmacodynamics and biomarkers. Disease activity assessments will include laboratory
      evaluation of acute phase reactants, pulmonary function testing, computed tomography of the
      neck and chest, electrocardiogram, echocardiogram, audiogram, physician assessment of
      chondritis activity, swollen and tender joint counts, and patient- and physican-reported
      outcomes. Adverse events and concomitant medications will be recorded.
    

Intervention name(s): Abatacept
Intervention type(s): Drug
Intervention description(s): 125 mg pre-filled syringe for sub-q injection weekly.
Other intervention name(s): Orencia
Intervention MeSH terms: Abatacept
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
Condition: Lupus Nephritis
MeSH terms: Nephritis; Lupus Nephritis
Study type: Interventional
Phase: Phase 3

Summary: 
      The objective of this study is to evaluate the efficacy and safety of Tacrolimus capsules for
      induction remission in patients with lupus nephritis, and compare the efficacy and safety
      with Cyclophosphamide injections.
    

Detailed description: 
      This is a randomized, open, 1:1 parallel controlled, multi-center, non-inferiority clinical
      study.
    

Intervention name(s): Tacrolimus capsules; Cyclophosphamide injections; Prednisone
Intervention type(s): Drug; Drug; Drug
Intervention description(s): oral; intravenous injection; oral
Other intervention name(s): Prograf
Intervention MeSH terms: Prednisone; Cyclophosphamide; Tacrolimus
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Tacrolimus; Cyclophosphamide; Prograf; lupus nephritis